Royalty Pharma Ranks 388th in $300M Volume Amid $2B+ Strategic Deals to Expand Biopharma Royalty Portfolio

. 8, , ranking 388th in the market. The stock remains focused on expanding its biopharma royalty portfolio through strategic deals. . . . Analysts note the company’s emphasis on oncology and rare disease assets as key growth drivers.

The firm’s Q2 earnings call highlighted margin pressures amid strategic investments, . Royalty’s board reshuffle, including ’s departure, adds governance scrutiny. Despite near-term volatility, . However, .

To run this back-test rigorously I need to pin down a few practical details that aren’t fully specified yet: 1. Universe definition • “All U.S. listed stocks” can be handled, but it’s data-heavy. • Alternatively we can restrict to a liquid benchmark universe such as the Russell 3000 (≈3 000 stocks) or S&P 1500 to speed things up. Which would you prefer? 2. Ranking & trade timing • Do you want to rank on the same-day volume (buy at the close, sell next-day close), or rank on the previous day’s volume (buy next-day open, sell next-day close)? • Which price should we use for execution: open or close? 3. ? • Equal-weight across the 500 names each day, correct? Once you confirm (or adjust) the above, I’ll generate the retrieval plan and run the back-test.